Teriparatide Treatment in Patients With Inherited Osteoporosis
NCT ID: NCT01360424
Last Updated: 2015-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
6 participants
INTERVENTIONAL
2011-05-31
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Teriparatide (PTH) and Bone Strength in Postmenopausal Women
NCT01155245
Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis
NCT00051558
Effects of Teriparatide in Postmenopausal Women With Osteoporosis
NCT00079924
Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
NCT00670501
Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis
NCT00259298
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
teriparatide
Teriparatide
Daily administration of teriparatide 20 ug s.c. for 24 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Teriparatide
Daily administration of teriparatide 20 ug s.c. for 24 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* lumbar spine or hip BMD T-score ≤ -2.5
* a written informed consent.
Exclusion Criteria
* generally accepted contraindications for the treatment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Helsinki University Central Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ville-Valtteri Välimäki
Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matti Välimäki, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Division of Endocrinology, Department of Medicine, Helsinki University Central Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Orthopaedics and Traumatology and Division of Endocrinology, Department of Medicine and Pediatric Endocrinology, Hospital for Children and Adolescents, Helsinki University Central Hospital
Helsinki, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010-019297-32
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
HUS-LTO-PTH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.